2020 CIS Annual Meeting : Immune Deficiency & Dysregulation North American Conference
Errataetall: |
ErratumIn: J Clin Immunol. 2020 Jul;40(5):788. - PMID 32653965 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
---|---|
Enthalten in: |
Journal of clinical immunology - 40(2020), Suppl 1 vom: 11. Apr., Seite 1-163 |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 10.02.2021 published: Print ErratumIn: J Clin Immunol. 2020 Jul;40(5):788. - PMID 32653965 Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1007/s10875-020-00764-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM309771757 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM309771757 | ||
003 | DE-627 | ||
005 | 20231225134640.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10875-020-00764-z |2 doi | |
028 | 5 | 2 | |a pubmed24n1032.xml |
035 | |a (DE-627)NLM309771757 | ||
035 | |a (NLM)32394034 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a 2020 CIS Annual Meeting |b Immune Deficiency & Dysregulation North American Conference |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 10.02.2021 | ||
500 | |a published: Print | ||
500 | |a ErratumIn: J Clin Immunol. 2020 Jul;40(5):788. - PMID 32653965 | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
650 | 4 | |a Congress | |
773 | 0 | 8 | |i Enthalten in |t Journal of clinical immunology |d 1981 |g 40(2020), Suppl 1 vom: 11. Apr., Seite 1-163 |w (DE-627)NLM012677426 |x 1573-2592 |7 nnns |
773 | 1 | 8 | |g volume:40 |g year:2020 |g number:Suppl 1 |g day:11 |g month:04 |g pages:1-163 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10875-020-00764-z |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 40 |j 2020 |e Suppl 1 |b 11 |c 04 |h 1-163 |